Search

Displaying results 4601 - 4610 of 10000 in total
  1. Drug

    Bexagliflozin

    go.drugbank.com/drugs/DB12236
    ApprovedInvestigational

    Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. … [A256413] SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly expressed in the kidney.

    Synonyms: D-glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1s)-, (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triolCategories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  2. Drug

    Tulobuterol

    go.drugbank.com/drugs/DB12248
    Investigational

    Tulobuterol has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.

    Categories: Selective Beta 2-adrenergic Agonists
  3. Drug

    Brigatinib

    go.drugbank.com/drugs/DB12267
    ApprovedInvestigational

    [A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. … Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).

    Mixtures: ALUNBRİG 90 MG VE 180 MG FİLM KAPLI TABLET TEDAVİYE BAŞLANGIÇ PAKETİ, 7 ADET 90 MG VE 21 ADET 180 MG, ALUNBRİG 90 MG VE 180 MG FİLM KAPLI TABLET TEDAVİYE BAŞLANGIÇ PAKETİ, 7 ADET 90 MG VE 21 ADET 180 MGCategories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, MATE 1 Inhibitors
  4. Drug

    Propiverine

    go.drugbank.com/drugs/DB12278
    Approved

    Propiverine is a widely used antimuscarinic drug with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB) [A32576]. … Propiverine hydrochloride is a bladder detrusor muscle relaxant drug with dual antimuscarinic and calcium-modulating properties for the treatment of OAB [L2317].

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: MICTONORM SR 30MG SÜREKLI SALIMLI KAPSÜL, MICTONORM SR 45MG SÜREKLI SALIMLI KAPSÜL
  5. Drug

    Dasotraline

    go.drugbank.com/drugs/DB12305
    Investigational

    Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention

  6. Drug

    Chlorproguanil

    go.drugbank.com/drugs/DB12314
    Investigational

    It is a dichloro-derivative of chloroguanide.

  7. Drug

    Ifetroban

    go.drugbank.com/drugs/DB12321
    Investigational

    Ifetroban has been used in trials studying the treatment of Skin Diseases, Autoimmune Diseases, Pathologic Processes, Scleroderma, Limited, and Scleroderma, Diffuse, among others.

    Categories: Heterocyclic Compounds, 1-Ring
  8. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive … This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Samidorphan

    go.drugbank.com/drugs/DB12543
    ApprovedInvestigational

    [A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability … [A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™

    Salts: Samidorphan L-malateCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    >A</sub>R and 0.8 nM for AT<sub>1</sub>R). … Sparsentan is a dual antagonist of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II (Ang II) type 1 receptor (AT<sub>1</sub>R) with a similar affinity for both (9.3 nM for ET<sub

    Categories: Angiotensin 2 Receptor Blocker, Dual Endothelin Type A Receptor/Ang II Subtype 1 Receptor Antagonist (DEARA)